Search

Your search keyword '"O'Brien, Susan"' showing total 155 results
Start Over Author "O'Brien, Susan" Journal leukemia & lymphoma
155 results on '"O'Brien, Susan"'

1. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

Author

Short, Nicholas J, Kantarjian, Hagop, Ravandi, Farhad, Huang, Xuelin, Xiao, Lianchun, Garcia-Manero, Guillermo, Plunkett, William, Gandhi, Varsha, Sasaki, Koji, Pemmaraju, Naveen, Daver, Naval G, Borthakur, Gautam, Jain, Nitin, Konopleva, Marina, Estrov, Zeev, Kadia, Tapan M, Wierda, William G, DiNardo, Courtney D, Brandt, Mark, O’Brien, Susan M, Cortes, Jorge E, and Jabbour, Elias

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Hematology, Pediatric, Pediatric Cancer, Childhood Leukemia, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Clofarabine, Cytarabine, Drug Resistance, Neoplasm, Humans, Idarubicin, Leukemia, Myeloid, Acute, Middle Aged, Neoplasm Recurrence, Local, Progression-Free Survival, Remission Induction, Survival Rate, Treatment Outcome, Vidarabine, Young Adult, Acute myeloid leukemia, relapsed, refractory, purine nucleoside analogues, clofarabine, fludarabine, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n = 48) or FIA (n = 33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p = .50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p = .48), and the median overall survival was 6.3 and 4.7 months, respectively (p = .28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.

Published
2018

2. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Author

Maiti, Abhishek, Cortes, Jorge, Ferrajoli, Alessandra, Estrov, Zeev, Borthakur, Gautam, Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, O’Brien, Susan, and Kantarjian, Hagop

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Blast Crisis, Female, Harringtonines, Homoharringtonine, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Neoplasm Staging, Retreatment, Treatment Outcome, Young Adult, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Published
2017

3. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

Author

Marvin-Peek, Jennifer, Jen, Wei-Ying, Kantarjian, Hagop M., McCue, David, Haddad, Fadi G., Wierda, William, Ferrajoli, Alessandra, Burger, Jan, Abusab, Tareq, Jorgensen, Jeffrey, Wang, Sa A., Patel, Keyur, Loghavi, Sanam, O'Brien, Susan, and Ravandi, Farhad

Subjects
HAIRY cell leukemia, DISEASE relapse, OVERALL survival, PATIENTS' attitudes, RITUXIMAB
Abstract

We report on the long-term efficacy and safety of a phase 2 trial of sequential cladribine and rituximab in hairy cell leukemia (HCL). One-hundred and thirty-nine patients were enrolled: 111 in the frontline setting, 18 in first relapse, and 10 with variant HCL (HCLv). A complete response (CR) was achieved in 133 of 137 evaluable participants (97%) with measurable residual disease (MRD) negativity in 102 (77%). MRD status was not associated with significant differences in event-free survival (EFS) or overall survival (OS). With a median follow-up of 7.8 years (range: 0.40–18.8), eight patients have experienced disease relapse (5.8%), 4/111 with newly diagnosed HCL (3·6%) and 4/10 with HCLv (40%) (p = 0.002). The 10-year EFS and OS rates were 86.7% and 91.1%, respectively. Grade 3 adverse events were observed in 28 participants (20·1%), mostly due to infections. Treatment of HCL with sequential cladribine followed by rituximab is associated with excellent efficacy and safety results both in the frontline and relapsed settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Management of adverse events associated with idelalisib treatment: expert panel opinion

Author

Coutré, Steven E, Barrientos, Jacqueline C, Brown, Jennifer R, de Vos, Sven, Furman, Richard R, Keating, Michael J, Li, Daniel, O’Brien, Susan M, Pagel, John M, Poleski, Martin H, Sharman, Jeff P, Yao, Nai-Shun, and Zelenetz, Andrew D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Patient Safety, Digestive Diseases, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Good Health and Well Being, Algorithms, Antineoplastic Agents, Class Ia Phosphatidylinositol 3-Kinase, Diet Therapy, Disease Management, Drug-Related Side Effects and Adverse Reactions, Enzyme Inhibitors, Expert Testimony, Hematologic Neoplasms, Humans, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Purines, Quinazolinones, Signal Transduction, TOR Serine-Threonine Kinases, Treatment Outcome, Idelalisib, phosphatidylinositol 3-kinase delta (PI3K) inhibitor, diarrhea, colitis, transaminitis, pneumonitis, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, Immunology, Cardiovascular medicine and haematology
Abstract

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. An expert panel was convened to review the pathology of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy. This article provides an overview of idelalisib TEAEs reported in clinical trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis. For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or intravenous steroid therapy.

Published
2015

5. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Author

Benjamini, Ohad, Jain, Preetesh, Trinh, Long, Qiao, Wei, Strom, Sara S, Lerner, Susan, Wang, Xuemei, Burger, Jan, Ferrajoli, Alessandra, Kantarjian, Hagop, O'Brien, Susan, Wierda, William, Estrov, Zeev, and Keating, Michael

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Orphan Drug, Pediatric, Rare Diseases, Pediatric Cancer, Clinical Research, Childhood Leukemia, Cancer, Prevention, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cell Transformation, Neoplastic, Cyclophosphamide, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Male, Middle Aged, Myelodysplastic Syndromes, Neoplasms, Second Primary, Retrospective Studies, Risk Factors, Rituximab, Survival Rate, Vidarabine, Lymphoid leukemia, chemotherapeutic approaches, pharmacotherapeutics, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence of second cancers, but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear. We report on the characteristics, incidence, outcomes and factors associated with second cancers in 234 patients receiving fludarabine, cyclophosphamide and rituximab (FCR) based regimens in the frontline setting. The risk of second cancers was 2.38 times higher than the expected risk in the general population. Ninety-three patients (40%) had other cancers before and 66 patients (28%) after FCR. Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5.1%) and Richter transformation (RT) (9%) were high, while solid tumors were not increased. Overall survival of patients with second cancers after frontline FCR was shorter (median of 4.5 years) compared to patients with and without prior cancers. Second cancer risk after frontline FCR is mainly due to high rates of t-AML/MDS and RT, and as speculated the survival of affected patients is shorter.

Published
2015

6. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor

Author

Chen, Yiming, Estrov, Zeev, Pierce, Sherry, Qiao, Wei, Borthakur, Gautam, Ravandi, Farhad, Kadia, Tapan, Brandt, Mark, O’Brien, Susan, Jabbour, Elias, Garcia-Manero, Guillermo, Cortes, Jorge, and Beran, Miloslav

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Childhood Leukemia, Rare Diseases, Cancer, Pediatric Cancer, Pediatric, Breast Cancer, Prevention, Hematology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Blood, Adult, Aged, Aged, 80 and over, Breast Neoplasms, Chemoradiotherapy, Female, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Mastectomy, Middle Aged, Multivariate Analysis, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Risk Factors, Survival Analysis, Survivors, Myeloid leukemias and dysplasias, chemotherapeutic approaches, prognostication, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.

Published
2015

7. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

Author

Poon, Michelle L, Fox, Patricia S, Samuels, Barry I, O’Brien, Susan, Jabbour, Elias, Hsu, Yvonne, Gulbis, Alison, Korbling, Martin, Champlin, Richard, Abruzzo, Lynne V, Bassett, Roland L, and Khouri, Issa F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research, Cancer, Stem Cell Research - Nonembryonic - Human, Clinical Research, Lymphoma, Rare Diseases, Hematology, Transplantation, Adult, Aged, Chromosome Deletion, Chromosomes, Human, Pair 17, Female, Follow-Up Studies, Graft vs Host Disease, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Referral and Consultation, Retrospective Studies, Stem Cell Transplantation, Survival Analysis, Survival Rate, Time Factors, Transplantation, Homologous, Treatment Outcome, 17p−, CLL, allogeneic transplant, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.

Published
2015

8. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Author

Benjamini, Ohad, Kantarjian, Hagop, Rios, Mary Beth, Jabbour, Elias, O’Brien, Susan, Jain, Preetesh, Cardenas-Turanzas, Marylou, Faderl, Stefan, Garcia-Manero, Guillermo, Ravandi, Farhad, Borthakur, Gautam, Quintas-Cardama, Alfonso, and Cortes, Jorge

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Hematology, Cancer, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Protein Kinase Inhibitors, Recurrence, Retreatment, Risk Factors, Time Factors, Treatment Outcome, CML, discontinuation, treatment, tyrosine kinase inhibitors, Immunology, Cardiovascular medicine and haematology
Abstract

Abstract With improved outcome for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), treatment discontinuation has become increasingly attractive to patients. We analyzed the outcomes of patients who chose to discontinue TKI therapy regardless of their ongoing response. Thirty-five patients with chronic phase CML discontinued TKI in complete cytogenetic response. Of them, 51% discontinued due to adverse effects, 23% due to long complete molecular response (CMR) (> 5 years), 9% due to pregnancy and 17% due to financial problems. After TKI discontinuation, patients were followed for a median of 16 months. Among 27 patients (77%) who discontinued TKIs in CMR, 11 (41%) had a molecular relapse after a median of 3.5 months. In univariate analysis we observed that patients with ≥ 64 months of CMR before TKI discontinuation had superior cumulative proportions of sustained CMR and major molecular response (MMR) at 12 months after discontinuation: 88.9% vs. 45.5% (p = 0.02) and 100% vs. 75% (p = 0.05), respectively. Patients treated with high dose imatinib or second generation TKIs had a higher cumulative proportion of sustained MMR at 12 months after discontinuation than patients treated with standard dose imatinib: 100% vs. 72.2% (p = 0.03), respectively. Of the five patients who stopped TKI in MR(4.5) (molecular response of 4.5-log reduction) one lost cytogenetic response. All three patients who discontinued TKIs in MMR lost cytogenetic response; one progressed to accelerated phase. Thirteen patients (37%) restarted TKIs after loss of response: 11 improved their response, and for two it is too early to assess. Treatment discontinuation can lead to sustained CMR in some patients, but risk of relapse is higher if patients discontinue TKIs when not in CMR.

Published
2014

9. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

Author

Strati, Paolo, Ferrajoli, Alessandra, Lerner, Susan, O’Brien, Susan, Wierda, William, Keating, Michael J, and Faderl, Stefan

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Infectious Diseases, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Cancer, Lymphoma, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Female, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Staging, Rituximab, Treatment Outcome, Vidarabine, Young Adult, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Fludarabine, cyclophosphamide and rituximab (FCR), the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia (CLL), is associated with a high rate of neutropenia and infectious complications. Granulocyte macrophage colony-stimulating factor (GM-CSF) reduces myelosuppression and can potentiate rituximab activity. We conducted a clinical trial combining GM-CSF with FCR for frontline treatment of 60 patients with CLL. Eighty-six percent completed all six courses and 18% discontinued GM-CSF for toxicity: grade 3-4 neutropenia was observed in 30% of cycles, and severe infections in 16% of cases. The overall response rate was 100%. Both median event-free survival (EFS) and overall survival (OS) have not been reached. Longer EFS was associated with favorable cytogenetics. GM-CSF led to a lower frequency of infectious complications than in the historical FCR group, albeit similar EFS and OS.

Published
2014

11. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma

Author

Siddiqi, Tanya, primary, Coutre, Steven, additional, McKinney, Matthew, additional, Barr, Paul M., additional, Rogers, Kerry, additional, Mokatrin, Ahmad, additional, Valentino, Rudy, additional, Szoke, Anita, additional, Deshpande, Sanjay, additional, Zhu, Angeline, additional, Arango-Hisijara, Israel, additional, Osei-Bonsu, Kojo, additional, Wang, Michael, additional, and O’Brien, Susan, additional

Published
2022
Full Text
View/download PDF

13. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Woyach, Jennifer, primary, Tedeschi, Alessandra, additional, Munir, Talha, additional, Siddiqi, Tanya, additional, Hillmen, Peter, additional, Byrd, John C., additional, Ghia, Paolo, additional, Mulligan, Stephen P., additional, Dai, Sandra, additional, Amaya-Chanaga, Carlos I., additional, Dean, James P., additional, O’Brien, Susan M., additional, and Barr, Paul M., additional

Published
2021
Full Text
View/download PDF

14. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis

Author

Yilmaz, Musa, primary, Kantarjian, Hagop M., additional, Toruner, Gokce, additional, Yin, C. Cameron, additional, Kanagal-Shamanna, Rashmi, additional, Cortes, Jorge E., additional, Issa, Ghayyas, additional, Short, Nicholas J., additional, Khoury, Joseph D., additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Kadia, Tapan, additional, Konopleva, Marina, additional, Wierda, William G., additional, Jain, Nitin, additional, Estrov, Zeev, additional, Sasaki, Koji, additional, Pierce, Sherry, additional, O'Brien, Susan M., additional, and Jabbour, Elias J., additional

Published
2020
Full Text
View/download PDF

15. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Author

Jabbour, Elias, primary, Stelljes, Matthias, additional, Advani, Anjali S., additional, DeAngelo, Daniel J., additional, Gökbuget, Nicola, additional, Marks, David I., additional, Stock, Wendy, additional, O’Brien, Susan, additional, Cassaday, Ryan D., additional, Wang, Tao, additional, Neuhof, Alexander, additional, Vandendries, Erik, additional, and Kantarjian, Hagop, additional

Published
2020
Full Text
View/download PDF

16. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis.

Author

Yilmaz, Musa, Kantarjian, Hagop M., Toruner, Gokce, Yin, C. Cameron, Kanagal-Shamanna, Rashmi, Cortes, Jorge E., Issa, Ghayyas, Short, Nicholas J., Khoury, Joseph D., Garcia-Manero, Guillermo, Ravandi, Farhad, Kadia, Tapan, Konopleva, Marina, Wierda, William G., Jain, Nitin, Estrov, Zeev, Sasaki, Koji, Pierce, Sherry, O'Brien, Susan M., and Jabbour, Elias J.

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, PROGNOSIS, ADULTS, DIAGNOSIS
Abstract

The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) at diagnosis. All 16 patients achieved complete remission after induction with intensive chemotherapy, and with a median of 7-year follow-up, 2 relapsed. The 5-year cumulative incidence of relapse and overall survival rates were 14% and 82%, respectively. Our analysis showed that adult patients with t(1;19)(q23;p13) positive ALL had favorable prognosis with intensive chemotherapy regimens. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

Author

Short, Nicholas J., primary, Kantarjian, Hagop, additional, Ravandi, Farhad, additional, Huang, Xuelin, additional, Xiao, Lianchun, additional, Garcia-Manero, Guillermo, additional, Plunkett, William, additional, Gandhi, Varsha, additional, Sasaki, Koji, additional, Pemmaraju, Naveen, additional, Daver, Naval G., additional, Borthakur, Gautam, additional, Jain, Nitin, additional, Konopleva, Marina, additional, Estrov, Zeev, additional, Kadia, Tapan M., additional, Wierda, William G., additional, DiNardo, Courtney D., additional, Brandt, Mark, additional, O’Brien, Susan M., additional, Cortes, Jorge E., additional, and Jabbour, Elias, additional

Published
2017
Full Text
View/download PDF

20. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

Author

Strati, Paolo, primary, Tong, Wei-Gang, additional, Vitale, Candida, additional, Wierda, William G., additional, O’Brien, Susan, additional, Brown, Jennifer R., additional, Weng, Wen-Kai, additional, Kipps, Thomas, additional, Keating, Michael J., additional, and Ferrajoli, Alessandra, additional

Published
2014
Full Text
View/download PDF

21. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Author

Benjamini, Ohad, primary, Jain, Preetesh, additional, Trinh, Long, additional, Qiao, Wei, additional, Strom, Sara S., additional, Lerner, Susan, additional, Wang, Xuemei, additional, Burger, Jan, additional, Ferrajoli, Alessandra, additional, Kantarjian, Hagop, additional, O'Brien, Susan, additional, Wierda, William, additional, Estrov, Zeev, additional, and Keating, Michael, additional

Published
2014
Full Text
View/download PDF

22. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide

Author

Eghtedar, Alireza, primary, Rodriguez, Ildefonso, additional, Kantarjian, Hagop, additional, O'Brien, Susan, additional, Daver, Naval, additional, Garcia-Manero, Guillermo, additional, Ferrajoli, Alessandra, additional, Kadia, Tapan, additional, Pierce, Sherry, additional, Cortes, Jorge, additional, and Ravandi, Farhad, additional

Published
2014
Full Text
View/download PDF

23. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor

Author

Chen, Yiming, primary, Estrov, Zeev, additional, Pierce, Sherry, additional, Qiao, Wei, additional, Borthakur, Gautam, additional, Ravandi, Farhad, additional, Kadia, Tapan, additional, Brandt, Mark, additional, O’Brien, Susan, additional, Jabbour, Elias, additional, Garcia-Manero, Guillermo, additional, Cortes, Jorge, additional, and Beran, Miloslav, additional

Published
2014
Full Text
View/download PDF

24. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

Author

Poon, Michelle L., primary, Fox, Patricia S., additional, Samuels, Barry I., additional, O’Brien, Susan, additional, Jabbour, Elias, additional, Hsu, Yvonne, additional, Gulbis, Alison, additional, Korbling, Martin, additional, Champlin, Richard, additional, Abruzzo, Lynne V., additional, Bassett, Roland L., additional, and Khouri, Issa F., additional

Published
2014
Full Text
View/download PDF

26. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

Author

Benjamini, Ohad, primary, Kantarjian, Hagop, additional, Rios, Mary Beth, additional, Jabbour, Elias, additional, O’Brien, Susan, additional, Jain, Preetesh, additional, Cardenas-Turanzas, Marylou, additional, Faderl, Stefan, additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Borthakur, Gautam, additional, Quintas-Cardama, Alfonso, additional, and Cortes, Jorge, additional

Published
2013
Full Text
View/download PDF

31. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

Author

Bashir, Qaiser, primary, De Lima, Marcos J., additional, Mcmannis, John D., additional, Garcia-Manero, Guillermo, additional, Shpall, Elizabeth, additional, Kantarjian, Hagop, additional, Cortes, Jorge E., additional, O'Brien, Susan M., additional, Jones, Dan, additional, Qazilbash, Muzaffar, additional, Wei, Wei, additional, Giralt, Sergio A., additional, Champlin, Richard E., additional, and Hosing, Chitra, additional

Published
2010
Full Text
View/download PDF

34. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

Author

Schlette, Ellen J., primary, Schlette, Ellen J., additional, Admirand, Joan, additional, Wierda, William, additional, Abruzzo, Lynne, additional, Lin, Katherine I., additional, O'Brien, Susan, additional, Lerner, Susan, additional, Keating, Michael J., additional, and Tam, Constantine, additional

Published
2009
Full Text
View/download PDF

37. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all- trans retinoic acid plus chemotherapy or with all- trans retinoic acid plus arsenic trioxide.

Author

Eghtedar, Alireza, Rodriguez, Ildefonso, Kantarjian, Hagop, O'Brien, Susan, Daver, Naval, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Kadia, Tapan, Pierce, Sherry, Cortes, Jorge, and Ravandi, Farhad

Subjects
LEUKEMIA, TRETINOIN, CANCER chemotherapy, ARSENIC trioxide, BREAST cancer, PANCREATIC cancer, PATIENTS
Abstract

The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all- trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin ( n = 54) or ATRA plus arsenic trioxide (ATO) ( n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers ( p = 0.29) adjusted for unit time of exposure. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

38. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series

Author

Tsimberidou, Apostolia-Maria, primary, Tirado-Gomez, Maribel, additional, Andreeff, Michael, additional, O'Brien, Susan, additional, Kantarjian, Hagop, additional, Keating, Michael, additional, Lopez-Berestein, Gabriel, additional, and Estey, Elihu, additional

Published
2006
Full Text
View/download PDF

42. Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival

Author

Giles, Francis J., primary, Shen, Yu, additional, Kantarjian, Hagop M., additional, Korbling, Martin J., additional, O'brien, Susan, additional, Anderlini, Paolo, additional, Donato, Michele, additional, Pierce, Sherry, additional, Keating, Michael J., additional, Freireich, Emil J., additional, and Estey, Elihu, additional

Published
2001
Full Text
View/download PDF

44. Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

Author

Dabaja, Bouthaina S., primary, O'brien, Susan M., additional, Kantarjian, Hagop M., additional, Cortes, Jorge E., additional, Thomas, Deborah A., additional, Albitar, Maher, additional, Schlette, Ellen S., additional, Faderl, Stefan, additional, Sarris, Andreas, additional, Keating, Michael J., additional, and Giles, Francis J., additional

Published
2001
Full Text
View/download PDF

49. Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia

Author

Sacchi, Stefano, primary, Kantarjian, Hagop M., additional, Freireich, Emil J, additional, O'brien, Susan, additional, Cortes, Jorge, additional, Rios, Mary Beth, additional, Kornblau, Steve, additional, Giles, Francis J., additional, Roller, Charles, additional, Gajewski, James, additional, and Talpaz, Moshe, additional

Published
1999
Full Text
View/download PDF

50. Sequential Cis-Platinum and Fludarabine with or without Arabinosyl Cytosine in Patients Failing Prior Fludarabine Therapy for Chronic Lymphocytic Leukemia: A Phase II Study

Author

Giles, Francis J., primary, O'brien, Susan M., additional, Santini, Valeria, additional, Gandhi, Varsha, additional, Plunkett, William, additional, Seymour, John F., additional, Robertson, Lester E., additional, Kantarjian, Hagop M., additional, and Keating, Michael J., additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results